Summary: A milestone neurobiology study has provided the first empirical, direct comparison of the two leading preclinical models used to study multiple sclerosis (MS). Investigating the destruction and regeneration of myelin, the protective fatty sheath surrounding nerve fibers, the research group analyzed the cuprizone (CPZ) and lysophosphatidylcholine (LPC) paradigms alongside real human MS tissue samples.
By utilizing single-cell RNA sequencing to map genetic alterations during demyelination, the study shatters the assumption that these models are interchangeable, providing a definitive scientific roadmap to help researchers choose the correct model for targeted MS drug development.
Key Facts
- The Myelin Insulator: Multiple sclerosis affects over 1 million Americans, causing the immune system to mistakenly strip away myelin, the protective coating that insulates neural axons like plastic around electrical wires.
- The Preclinical Mandate: Because collecting viable, live brain and spine tissue from progressive MS patients is exceptionally challenging, science relies heavily on preclinical animal models to test therapeutic concepts.
- Deconstructing CPZ vs. LPC: While both paradigms induce demyelination, they operate on wildly different structural and chronological scales; CPZ triggers widespread myelin loss over several weeks, whereas LPC induces a single, highly localized lesion within days.
- Cellular Specificity Guidance: The study proves CPZ is superior for analyzing the stress, death, and repair mechanics of myelin-producing cells due to its gradual timeline. Conversely, LPC is optimal for mapping aggressive, acute autoimmune responses.
- Genetic Mapping to Human Tissue: The research group built single-cell genetic maps of the lesions from both models and matched them directly against human MS tissue to ensure future treatments are clinically relevant.
- The Unreached Therapeutic Frontier: Modern MS drugs focus almost exclusively on suppressing autoimmune flare-ups; physically regenerating lost myelin within established neural lesions remains a promising but currently unrealized medical target.
Source: University of Notre Dame
More than 1 million people across the United States live with multiple sclerosis (MS), a disease that affects the brain, optic nerves and spine.
MS is an unpredictable disorder, with symptoms — such as overwhelming fatigue, muscle spasms and vision problems — flaring up and then subsiding over days, months or even years. To identify new treatment paradigms for MS, studying the underlying damage to the nervous system is key.
Katrina Adams, a neurobiologist at the University of Notre Dame, studies the role that the loss and regeneration of myelin plays in MS progression. A fatty substance that protects nerve cells, myelin envelopes the axons of the brain as they route the electrical signals that carry information throughout the nervous system, similar to how plastic insulation protects electrical wires. The damage and swelling that follow myelin loss in MS form distinct “lesions,” which vary in size, number and location in the nervous system.
Because collecting viable tissue samples from patients with progressive disease is a challenge, scientists rely on preclinical biological models.
A new study from the Adams research group, out today in Nature Communications, empirically compares for the first time two prevailing models — cuprizone (CPZ) and lysophosphatidylcholine (LPC) — for the study of myelin loss and regeneration in MS.
“Our analysis of these two models of myelin loss and regeneration provides a road map based on robust scientific evidence that we hope will advance the study of MS and related diseases,” said Adams, who is the Gallagher Assistant Professor in the Department of Biological Sciences.
The CPZ and LPC paradigms are used largely interchangeably. But while both models degrade myelin, the timeline and localization of myelin loss varies between the two. CPZ causes widespread loss of myelin over several weeks. LPC, on the other hand, induces a lesion in just one place within days.
This new research, which was funded by the National Multiple Sclerosis Society, points to specific scenarios in which one model is better suited, depending on which aspect of MS is under investigation.
“If you’re studying the myelin-producing cells and what’s happening to them in MS — are they stressed, dying or trying to repair? — CPZ is better, since the loss of myelin is more gradual,” Adams said.
“For studying the immune cells that respond to the myelin loss, LPC may be better, since the immune response is more aggressive than in CPZ.”
Beyond comparing CPZ and LPC to each other, Adams’ team also analyzed the resulting lesions from each preclinical model alongside data obtained from human MS tissue samples. The researchers constructed genetic maps of each type of tissue with the help of single-cell RNA sequencing, allowing them to examine the genetic changes that occurred in response to demyelination.
“By matching each model to features seen in diseased tissue from real patients, we can be sure that we’re targeting things that are actually causing disease in human patients,” Adams said.
“There are so many potential paths to follow, so we want to make sure that the path chosen has direct relevance to MS patients.”
In addition to phenotypic differences, the genetic changes in diseased cells vary between the two models — an area of future exploration for the Adams research group.
“We were surprised to see several interesting genetic variations in some cell types, but we don’t yet know if these changes encourage or discourage myelin regeneration,” Adams said.
“Learning more about these shifts in gene expression may reveal how MS affects the nervous system and how the body responds to it, which is essential groundwork for developing new therapies.”
Since MS flare-ups are primarily triggered by the immune system’s reaction to lesions — which also attacks healthy cells — current clinical treatments focus on quelling this autoimmune response. The regeneration of lost myelin within MS lesions, on the other hand, remains a promising yet unrealized drug target.
“The strategic use of these two preclinical models is essential for translating insights into therapies that might restore lost myelin,” Adams said. “We need to better understand the very process of demyelination in order to treat one of the root causes of this debilitating disorder.”
Key Questions Answered:
A: For decades, researchers treated CPZ and LPC as interchangeable because they yield the same end result: myelin loss. However, this study proves they leave completely different genetic and cellular footprints. If you use the wrong model, you risk testing a drug on a biological path that has zero relevance to how multiple sclerosis actually behaves in a real human patient.
A: Current clinical therapies are defensive; they work by calming down the immune system to prevent it from launching new autoimmune attacks against healthy tissue. The holy grail of MS research, actively going into an existing lesion and regenerating the lost myelin coating, remains an unrealized drug target. This study provides the exact blueprint needed to transition from defensive immune-suppression to offensive nerve repair.
A: It allows scientists to look at individual cells and read exactly which genes are switching on or off in response to damage. By running single-cell sequencing on lesions from both lab models and human MS tissue, the Notre Dame team can literally match the genetic variations. If a specific cell type shows the exact same genetic shift in the CPZ model as it does in a human patient, scientists know they have found a verified target for drug discovery.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by our staff.
About this multiple sclerosis research news
Author: Brandi Wampler
Source: University of Notre Dame
Contact: Brandi Wampler – University of Notre Dame
Image: The image is credited to Neuroscience News
Original Research: Open access.
“A comparative transcriptomic analysis of mouse demyelination models and multiple sclerosis lesions” by Erin L. Aboelnour, Veronica R. Vanoverbeke, Elizabeth A. Maupin, Madelyn M. Hatfield & Katrina L. Adams. Nature Communications
DOI:10.1038/s41467-026-72383-y
Abstract
A comparative transcriptomic analysis of mouse demyelination models and multiple sclerosis lesions
Demyelinating diseases, including multiple sclerosis (MS), are characterized by loss of myelin and progressive neurodegeneration. It remains unclear if demyelination mouse models, such as cuprizone (CPZ) and lysophosphatidylcholine (LPC) elicit distinct responses or are comparable to human disease.
Here, we integrate new and published single-cell transcriptomic datasets from CPZ- and LPC-induced demyelination and compare them with human MS data. We find that CPZ induces a distinct, stressed oligodendrocyte (OL) state, marked by Cdkn1a and Nupr1, that resembles phenotypes in MS lesions.
The models converge on an immune responsive OL state expressing Socs3, B2m, and interferon-response genes during remyelination. Mouse microglia share a conserved activation program, although LPC drives a stronger, prolonged response. However, neither model captures the oligodendrocyte progenitor and microglial heterogeneity observed in MS.
These results provide a cross-model, cross-species atlas of glial states and offer a framework to strategically leverage mouse models to study myelin injury and repair.
